APUM7 Antibody
Product Specs
Target Background
Q&A
Based on analysis of 7 research publications about monoclonal antibodies (7A6/APO2.7 and related clones), here are structured FAQs addressing key research considerations:
Advanced Research Questions
How to resolve discordance between APO2.7 detection and caspase activation assays?
Data Contradiction Analysis Framework:
-
Temporal mapping: APO2.7 appears earlier (1-3hr post-stimulation) vs caspases (4-6hr)
-
Pathway analysis:
-
Mitochondrial vs death receptor pathways
-
Test Bcl-2 inhibitors vs TRAIL treatment
-
-
Multispectral cytometry: Co-stain with MitoTracker Red (ΔΨm loss correlation)
What optimization strategies improve 7A6 performance in complex tissues?
Methodological Recommendations:
-
Tissue dissociation: Collagenase IV (2mg/ml) + DNase I (100U/ml) preserves epitopes
-
Fixation: 4% PFA <20min maintains antigenicity vs methanol degradation
-
Autofluorescence reduction: 0.1% Sudan Black B in 70% ethanol
How to design longitudinal in vivo studies using 7A6-related antibodies?
Pharmacokinetic Considerations:
| Parameter | Whole mAb (7A7) | F(ab')₂ Fragment |
|---|---|---|
| t₁/₂ β | 23.9 hrs | 2.4 hrs |
| AUC₀-∞ | 148 μg·hr/ml | 16 μg·hr/ml |
| Target Organ | Lungs (38% ID/g) | Spleen (12% ID/g) |
Dosing Strategy:
-
Whole mAb: Single dose (10mg/kg) sufficient for 72hr coverage
-
Fragments: Q12h dosing required for sustained effect
Technical Validation Questions
How to address batch variability in 7A6-based apoptosis assays?
QC Protocol:
-
Lot testing: ≥5 donors with known apoptosis response
-
Standard curve: H₂O₂ titration (0-5mM) → R² >0.95
-
Inter-lab calibration: Exchange 10% samples with reference lab
What orthogonal methods confirm 7A6 antibody specificity?
Validation Matrix:
| Method | Target | Concordance Threshold |
|---|---|---|
| WB | 38kDa band | >90% intensity match |
| IHC | Mitochondrial pattern | Cohen's κ >0.75 |
| CRISPR | ANT2 knockdown | ≥60% signal reduction |
References integrated from:
